Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Virpax Pharmaceuticals ( (VRPX) ).
Virpax Pharmaceuticals has amended its Independent Contractor Agreements with CEO Jatinder Dhaliwal and CFO Usama Chaudhry to align them with their intended structure. These amendments clarify that the services of Mr. Dhaliwal and Mr. Chaudhry are provided through their respective Canadian corporations, Jat Consulting Corp. and Chaudhry U Consulting Inc., and address tax responsibilities and compliance with applicable laws, ensuring proper operational structuring and legal adherence.
More about Virpax Pharmaceuticals
Virpax Pharmaceuticals operates within the pharmaceutical industry, focusing on the development of non-addictive pain management products and treatments for central nervous system disorders. The company aims to advance innovative therapies to enhance the quality of life for patients.
YTD Price Performance: -87.19%
Average Trading Volume: 3,631,412
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.32M
See more insights into VRPX stock on TipRanks’ Stock Analysis page.
